Table 3:

DT MR imaging metrics of specific WM tracts in patients with ALS and healthy controls

FAMD (× 10−3 mm2 s−1)radD (× 10−3 mm2 s−1)AxD (× 10−3 mm2 s−1)
HCALSHCALSHCALSHCALS
CC0.62 ± 0.030.61 ± 0.030.76 ± 0.040.79 ± 0.05*§0.44 ± 0.040.47 ± 0.05§1.40 ± 0.061.44 ± 0.05
CSTR0.67 ± 0.030.63 ± 0.04*§#0.71 ± 0.020.75 ± 0.04*§#0.37 ± 0.020.43 ± 0.04**§#1.37 ± 0.071.38 ± 0.05
L0.67 ± 0.030.63 ± 0.03*§#0.71 ± 0.030.76 ± 0.04*§#0.38 ± 0.020.44 ± 0.05**§#1.37 ± 0.081.39 ± 0.05
SLFR0.49 ± 0.030.47 ± 0.030.73 ± 0.040.77 ± 0.06*§0.51 ± 0.040.55 ± 0.06*1.15 ± 0.061.20 ± 0.07*§
L0.49 ± 0.030.48 ± 0.030.74 ± 0.030.77 ± 0.05*§0.52 ± 0.040.55 ± 0.05*§1.18 ± 0.051.21 ± 0.06
CingulumR0.57 ± 0.040.57 ± 0.030.73 ± 0.030.76 ± 0.05*§0.46 ± 0.040.49 ± 0.051.27 ± 0.061.32 ± 0.06*
L0.57 ± 0.040.56 ± 0.030.75 ± 0.050.78 ± 0.050.48 ± 0.060.50 ± 0.051.31 ± 0.061.35 ± 0.07
IFOFR0.55 ± 0.030.54 ± 0.030.80 ± 0.040.82 ± 0.060.52 ± 0.050.55 ± 0.051.34 ± 0.051.38 ± 0.80§
L0.53 ± 0.040.52 ± 0.020.81 ± 0.050.84 ± 0.060.54 ± 0.050.57 ± 0.051.34 ± 0.061.39 ± 0.083
ILFR0.46 ± 0.030.45 ± 0.020.81 ± 0.050.84 ± 0.060.60 ± 0.050.62 ± 0.051.23 ± 0.061.27 ± 0.087
L0.47 ± 0.040.46 ± 0.030.81 ± 0.060.83 ± 0.050.58 ± 0.060.61 ± 0.051.26 ± 0.081.27 ± 0.06
UncinateR0.43 ± 0.030.42 ± 0.030.79 ± 0.040.83 ± 0.06*§0.59 ± 0.040.63 ± 0.06*§1.20 ± 0.051.25 ± 0.07*§
L0.41 ± 0.030.42 ± 0.030.82 ± 0.050.86 ± 0.06*§0.62 ± 0.050.65 ± 0.061.20 ± 0.071.29 ± 0.07*§#
Fornix0.40 ± 0.050.40 ± 0.031.18 ± 0.231.22 ± 0.180.93 ± 0.020.96 ± 0.021.67 ± 0.201.73 ± 0.17

  • Note:—Values are means ± SD; HC indicates healthy controls; radD, radial diffusivity; AxD, axial diffusivity; CC, corpus callosum.

  • ↵* P <0.05 and

  • ↵** P <0.001 in patients with ALS versus HC;

  • ↵§ P < .05 in patients with ALS who scored below the cutoff in at least one cognitive test versus HC, and

  • ↵# P <.05 in patients with ALS with normal cognitive tests versus HC, according to the multivariate linear models adjusted for age (see text for details).